The Relevance of Continuous Solid Oral Dosage Processing and NIR Spectroscopy In Meeting the Needs of QbD and PAT - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Relevance of Continuous Solid Oral Dosage Processing and NIR Spectroscopy In Meeting the Needs of QbD and PAT
The author discusses control strategies via near infrared instrumentation for continuous mixing, granulation, drying, and extrusion with a more focused detail on mixing.


Pharmaceutical Technology
Volume 33, Issue 10, pp. 112-120

References

1. FDA, "Pharmaceutical CGMPs for the 21st Century: A Risk-Based Approach," (Rockville, MD, Aug. 2002).

2. K. Stryczek et al., "Capitalizing on Aggregate Data for Gaining Process Understanding-Effect of Raw Material, Environmental and Process Conditions on the Dissolution Rate of a Sustained Release Product," J. Pharm. Innov. 2 (1–2), 6–17 (2007).

3. FDA, Draft Guidance for Industry, Process Validation: General Principles and Practices (Rockville, MD, November 2008).

4. ISA, ANSI/ISA S95.00.03, Enterprise-Control System Integration-Part 3: Activity Models for Manufacturing Operation Management (Raleigh, NC, 2005).

5. J. Hirsch and T. Strother, "Lactose Particle Size Analysis Using FT-NIR Spectroscopy," Application Note 51557, Thermo Fisher Scientific, Madison, WI (2007).

6. I. T. Cameron and F. Y. Wang, "Granulation Process Modeling," in the Handbook of Pharmaceutical Granulation Technology, D. M. Parikh, Ed. (Taylor & Francis, Boca Raton, FL, 2nd ed), pp. 555–590 (2005).

7. R. P. Cogdill et al., "The Financial Returns on Investment in Process Analytical Technology and Lean Manufacturing: Benchmarks and Case Study," J. Pharm. Innov. 2 (1–2), 38–50 (2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here